Daily Market Digest Thur 6 Jan: Pathology stocks fall as Aus Govt votes in rapid antigen, tech stocks see carnage, Pfizer due for boost

Daily Market Digest Thur 6 Jan: Pathology stocks fall as Aus Govt votes in rapid antigen, tech stocks see carnage, Pfizer due for boost

Equities 4 minutes to read
Jessica Amir

Market Strategist

Summary:  Asian and Australian markets follow US lower as the Fed hints interest rates hikes could come quicker and faster. US tech stocks crumble, taking selling in tech and profitless stocks to a 10 year high. Pathology companies fall from record highs as the Australian Fed Gov says Aussies can take rapid antigen tests over PCR. Pfizer’s booster is approved and its share look ripe for a rally. Plus, why lithium, EVs and oil stocks are revving up.


Firstly  -  what you need to know now and consider

  • Beware of mounting tech and profitless stock selling: Professional investors spent December selling high-growth, high-valuation stocks ahead of the US Fed hiking rates in 2022, AND overnight, SELLING INTENSIFIED after the Federal flagged the chance of earlier and faster interest rate hikes. Sales in profitless tech stocks hit its highest level in 10 year. The technical indicators suggest the Nasdaq for instance is susceptible to another pull back on the hourly and daily chart.
  • In Australia, Afterpay, which was the biggest tech stock in Australia has today fallen 9.7% to $72.66, its lowest price since September 2020 as trading volume in the stock doubled its 20-day average, showing that investors are running for the hills out of stocks that carry high -debt and don’t make a profit. Afterpay shares have tanked 35% year-on-year and Morgans cut Afterpay’s price target by 31% following the founders and insiders reducing their holdings in the buy now pay later giant. It also follows Tencent Holdings reducing its stake in Afterpay to 4.86% last year. Afterpay shares on the hourly, daily and weekly chart suggest further selling could come for holders of Afterpay. However the RSI indicators the stocks has been oversold. So beware if you are trading this.
  • Health companies are in focus again for two reasons, firstly Pfizer and BioNTech’s booster got US approval to be used in teens (people aged 12 to 17). The CDC has already approved Pfizer-BioNTech’s booster and Moderna’s booster for those over 18, and said they are preferred over Johnson & Johnson. Pfizer’s shares have been hovering around the same level since late October, however now the daily and weekly technical indicators such as the MACD and the RSI look interesting suggesting, Pfizer shares could be due for a rally.
  • The second reason healthcare stocks will be in focus for the rest of the week is because The Australian government wound back testing requirements - so people will now be able to take a rapid antigen tests without the need for a PCR test. Meaning, pathology giants like Sonic Healthcare and Australian Clinical Labs will be tested by investors and both shares in SHL and ACL are likely to fall further from their record all-time highs.
  • Oil stocks again a focus with  the price of oil trading bat $77.17 (Crude WTI ), and now facing further upward pressure as Mexico plans to halt crude exports by 2023. If this proves true it will remove one of the largest oil sellers from the market and push long-date oil prices higher. Our group thinking is that the price of oil could soon hit $100 a barrel as demand improves while weather extremities worsen.
  • In other big news, Lithium and battery minerals and electric vehicle stocks have also been thrust into the limelight this year as some of the best performers so far in 2022. Pilbara Minerals, and Alkem on the ASX are both of are up over 1% in 3 days. The battery minerals and EV ETF ACDC is flat, while overseas, the gains are far more exciting. For the worlds biggest auto makers; Toyota shares are up 5.7%, and VW shares are up 8.3% year to date.  One of the reasons is that last month, within five days of each other - both Toyota Motor Corp and Volkswagen laid out mass production plans to splurge $170 billion over the coming years to preserve their claim on an industry and transition from internal combustion engines to electric. Interestingly VW and Toyota sold 10 or 11 cars for every one Tesla sold in 2021. Despite that, Tesla is the most valuable listed car company.

Secondly, watch companies with Australian analyst rating changes

  • PDL: Pendal Group Raised to Outperform at Credit Suisse; PT A$7.20
  • APT: Morgans cut its PT on the stock by 31%.
  • PME: Pro Medicus Cut to Reduce at Morgans Financial Limited

Thirdly, watch companies in the news

  • Paladin shares pump 4% putting uranium companies back in the limelight; Uranium prices appear likely to rise as Kazakhstan, the world’s largest producer of the radioactive metal, struggles to cope with deadly protests that pose the biggest challenge to the country’s leadership in decades.
  • Serbia Seeks Safety Assurances on Rio Tinto Lithium Project: Serbia won’t let Rio Tinto mine its lithium without assurances that the company’s $2.4 billion project in the Balkan country is environmentally safe even as it offers huge economic benefits, a top government official says. Rio, committed the funds in July with plans to tap into one of Europe’s largest lithium deposits as global demand grows for battery material.
  • BHP (AU): ‘Thirsty Copper Mines Turn to the Sea as Chile Water Debate Rages
  • Ramsay Health Care (RHC AU): will recruit 550 graduate nurses next month in effort to combat chronic labor shortages: Australian
  • Aristocrat's Playtech Bid Likely to Be Rejected: Playtech Adjourns Holder Vote on Aristocrat Offer to Feb. 2. Playtech’s current share price (731.5p) suggests investors will reject Aristocrat’s 680p/share bid, even if a rival offer from JKO Play fails to materialize, writes Ivor Jones, an analyst at Peel Hunt (hold).
  • The Bank of Queensland’s ROE May Stick at 8% Due to Weak Revenue and Branch Assets: BOQ's ‘Revenue-to-Assets Inferior’.
  • Shareholder Events: WMC AU

Markets -  The numbers

  • Global Markets; In the US Dow Average down 0.2% to 36,713.26, the Nasdaq fell 3.3%. In Europe  FTSE 100 rose 0.6% to 7,341.66. The German Dax rose 0.7%.
  • CommoditiesIron ore futures are up 1.2% to $125.75. Gold spot up 0.3% to $1,819.70, Brent futures up 1.0% to $80.79/bbl
  • Currencies: Euro up 0.3% to $1.1320, Aussie up 0.1% to 0.7244 per US$, Kiwi little changed at 0.6813 per US$
  • Bonds: U.S. 10-year yield rose 4.6bps to 1.6929%. Australia 3-year bond yield rose 0.5bps to 1.15%, Australia 10-year bond yield rose 4bps to 1.79%

Quarterly Outlook

01 /

  • Equity outlook: The high cost of global fragmentation for US portfolios

    Quarterly Outlook

    Equity outlook: The high cost of global fragmentation for US portfolios

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: Commodities rally despite global uncertainty

    Quarterly Outlook

    Commodity Outlook: Commodities rally despite global uncertainty

    Ole Hansen

    Head of Commodity Strategy

  • Upending the global order at blinding speed

    Quarterly Outlook

    Upending the global order at blinding speed

    John J. Hardy

    Global Head of Macro Strategy

    We are witnessing a once-in-a-lifetime shredding of the global order. As the new order takes shape, ...
  • Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Quarterly Outlook

    Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Jacob Falkencrone

    Global Head of Investment Strategy

  • Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    Quarterly Outlook

    Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    John J. Hardy

    Global Head of Macro Strategy

  • Equity Outlook: The ride just got rougher

    Quarterly Outlook

    Equity Outlook: The ride just got rougher

    Charu Chanana

    Chief Investment Strategist

  • China Outlook: The choice between retaliation or de-escalation

    Quarterly Outlook

    China Outlook: The choice between retaliation or de-escalation

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: A bumpy road ahead calls for diversification

    Quarterly Outlook

    Commodity Outlook: A bumpy road ahead calls for diversification

    Ole Hansen

    Head of Commodity Strategy

  • FX outlook: Tariffs drive USD strength, until...?

    Quarterly Outlook

    FX outlook: Tariffs drive USD strength, until...?

    John J. Hardy

    Global Head of Macro Strategy

  • Fixed Income Outlook: Bonds Hit Reset. A New Equilibrium Emerges

    Quarterly Outlook

    Fixed Income Outlook: Bonds Hit Reset. A New Equilibrium Emerges

    Althea Spinozzi

    Head of Fixed Income Strategy

None of the information provided on this website constitutes an offer, solicitation, or endorsement to buy or sell any financial instrument, nor is it financial, investment, or trading advice. Saxo Capital Markets UK Ltd. (Saxo) and the Saxo Bank Group provides execution-only services, with all trades and investments based on self-directed decisions. Analysis, research, and educational content is for informational purposes only and should not be considered advice nor a recommendation. Access and use of this website is subject to: (i) the Terms of Use; (ii) the full Disclaimer; (iii) the Risk Warning; and (iv) any other notice or terms applying to Saxo’s news and research.

Saxo’s content may reflect the personal views of the author, which are subject to change without notice. Mentions of specific financial products are for illustrative purposes only and may serve to clarify financial literacy topics. Content classified as investment research is marketing material and does not meet legal requirements for independent research.

Before making any investment decisions, you should assess your own financial situation, needs, and objectives, and consider seeking independent professional advice. Saxo does not guarantee the accuracy or completeness of any information provided and assumes no liability for any errors, omissions, losses, or damages resulting from the use of this information.

Please refer to our full disclaimer for more details.

Saxo
40 Bank Street, 26th floor
E14 5DA
London
United Kingdom

Contact Saxo

Select region

United Kingdom
United Kingdom

Trade Responsibly
All trading carries risk. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more
Additional Key Information Documents are available in our trading platform.

Saxo is a registered Trading Name of Saxo Capital Markets UK Ltd (‘Saxo’). Saxo is authorised and regulated by the Financial Conduct Authority, Firm Reference Number 551422. Registered address: 26th Floor, 40 Bank Street, Canary Wharf, London E14 5DA. Company number 7413871. Registered in England & Wales.

This website, including the information and materials contained in it, are not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in the United States, Belgium or any other jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation.

It is important that you understand that with investments, your capital is at risk. Past performance is not a guide to future performance. It is your responsibility to ensure that you make an informed decision about whether or not to invest with us. If you are still unsure if investing is right for you, please seek independent advice. Saxo assumes no liability for any loss sustained from trading in accordance with a recommendation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Android is a trademark of Google Inc.

©   since 1992